Navin Fluorine International Ltd Q1 FY2027 Concall Summary

Key Takeaways

• All-cylinders quarter, 44% revenue growth: Revenue rose 44% YoY, EBITDA 73% YoY, and PAT 108% YoY, with all three verticals delivering strong performance and the company turning net debt free.
• R32 capacity bet is the core equity story: Management is adding 15,000 tons of R32 capacity against a decade-long backdrop of doubling demand and halving quota-driven supply, and expects operating leverage to support margins in any pricing environment.
• CDMO is graduating from promise to proof: Revenue grew 82% YoY, Phase 2 capex is fully dedicated to an existing European partner, and three more molecules head to FDA readout in 8–12 months, de-risking the pipeline.
• Advanced materials is the next leg, seeded now: A ₹90 crores adoption capacity capex was approved to qualify 4–5 lab-approved products at commercial scale, with a stated ambition to make this vertical as material as CDMO is today by decade-end.
• What to watch next quarter: Chemours project completion, progress on R32 contractual offtake (target 35–45%), and any early revenue signals from the advanced materials adoption capacity.

R32: The Capacity Bet and Its Logic

• Demand-supply asymmetry: Over a decade, R32 demand is expected to double while quota-driven supply shrinks to half, creating a structural deficit that Navin is positioning to serve from its integrated Indian base.
• Capacity scale-up: Navin currently has 9,000–10,000 tons of R32 capacity and is adding a further 15,000 tons, with commissioning targeted for Q3 FY27. The combined scale is designed to deliver operating leverage that supports both EBITDA growth and margin growth.
• Global, not Indian, market: India will be oversupplied for five years, so Indian players will service export markets; the real payoff is expected beyond 2027 as China undergoes a supply cut.
• Cost competitiveness: An integrated HF value chain, ongoing productivity improvements, and a hybrid power project (60% renewable) are expected to keep Navin the most competitive cost manufacturer.
• Contracting strategy: Navin has already signed a couple of HFC offtake contracts and is in advanced conversations to contract 35–45% of total R32 capacity over a five-year period, while deliberately maintaining an open position on the balance.

Ganatra: "For Navin, the operating leverage on 32 is going to be fantastic. And that will play out in our favor and support the EBITDA growth and the margin growth, frankly, in any pricing environment."

CDMO: Deepening the Anchor, Broadening the Pipeline

• Growth and visibility: CDMO revenue grew 82% YoY to ₹180 crores, with improved visibility driven by a balanced portfolio across commercial, late-stage, and early-stage programs spanning oncology, respiratory, cardiovascular, neurology, and animal health.
• European partner deepening: Phase 2 cGMP4 capex of ₹125 crores (operational by Q4 FY27) is entirely dedicated to the existing European CDMO partner, reflecting increasing demand on the current molecule. Navin is also entering into an MSA for an extra molecule in the same supply chain, taking participation to "API minus 1" level.
• Pipeline de-risking: Three more molecules are expected to go to FDA readout over the next 8–12 months, adding to a portfolio of 30–40 actively worked molecules, roughly 10 in late stage, and working relationships with all top 20 pharma companies.
• Asset productivity: The ₹288 crores cGMP4 capex is expected to achieve a 3x asset turn by FY29 or sooner, and the business remains on track for the $100 million revenue target this year.
• Portfolio philosophy: Management explicitly frames the multi-molecule approach as insurance against single-molecule approval risk, noting "there is enough in the pipeline to not worry about an outlier."

Ganatra: "The deepening of relationship is actually a great opportunity because it gives us a strong baseload on which we can work, and that's exactly what we've done."

Advanced Materials: Seeding the Next Vertical

• Strategic intent: Management aims to make advanced materials a material business unit by the end of the decade, comparable in scale to what CDMO is today, focused on niche applications in data centers, electronics, defense, and semiconductors.
• Adoption capacity capex: The board approved ₹90 crores for adoption capacities at the Surat site, with Phase 1 completion expected toward the middle of Q4 FY27. This will allow 4–5 lab-qualified products to enter commercial-scale qualification while the next set of 4–5 products progresses through the pipeline.
• End-market applications: Target areas include chip fabrication, chip cooling, OLED display manufacturing, data center fire suppressants, high-voltage electrical applications, wind energy, and advanced intermediates for fluoroelastomers, sealants, films, and coatings.
• Supply-chain positioning: Management believes Navin is "one of the most credible supply chain partners" for customers looking to derisk their fluorination supply chains, a positioning that underpins the commercial qualification strategy.
• Chemours anchor: Navin is the sole supplier to Chemours for a two-phase cooling liquid, and the dedicated project is targeted for completion by end of Q2 FY27, forming part of the advanced materials vertical.
• DRDO partnership: Navin is partnering with DRDO on a critical TDF project to indigenize a highly critical imported specialty material; the product has applications beyond defense, representing a material opportunity the company can pursue independently.

Ganatra: "To be honest, we would probably be one of the most credible supply chain partners over here if somebody is looking to derisk their supply chain."

Specialty Chemicals: Volume-Led Recovery with Pricing Pressure

• Growth rebound: Specialty chemicals revenue grew 48% YoY to ₹325 crores after a subdued FY25, driven by the ramp-up of commissioned capex and participation in five new molecules, three of which are patented and do not face typical pricing pressure.
• Volume over price: Growth is predominantly volume-led, with pricing playing a minimal role; pricing pressure continues, particularly in the well-supplied Latin American market.
• New molecule visibility: Strong visibility exists for campaign orders of four to five molecules in the agchem space this year, giving management confidence in growth for both this year and next.
• MPP debottlenecking: Debottlenecking at Dahej MPP facilities is expected to complete by Q3 FY27, adding capacity at a 2x asset turn, which management describes as "unheard of in the agchem space."
• Margin philosophy: Management is not expecting a return to 30% EBITDA margins in specialty chemicals; the focus is on driving productivity gains and efficiencies from the expanded asset base.

Margins, Cash Flow, and Capital Allocation

• Margin expansion: Operating EBITDA margin stood at 34.2%, up 566 bps YoY, supported by operating leverage and a favorable HFC pricing environment.
• Gross margin pressure: Gross margins dipped approximately 100 bps QoQ due to heightened global war tensions, supply chain risk, and increasing raw material costs; management noted a lag effect in passing through RM inflation to product prices, partially offset by productivity improvements.
• Near-term margin outlook: Management expects EBITDA margins in the 32–33% range, plus or minus 1%, supported by new HFC capacity, the debottlenecking plant, and the Chemours project providing operating leverage confidence.
• Balance sheet strength: The company turned net debt free during the quarter, with operating cash flows of ₹173 crores and net working capital at 81 days of sales, within its financial framework.
• Capex discipline: All capex passes through stage gates covering technical evaluation, commercial evaluation, and financial framework before board approval; projects are derisked through both product plays (engagement-based visibility) and service plays (backed by order projections and commitments).

Ganatra: "We will only pursue those CapExes which are value accretive, and that's what our sort of discipline around investment guides us to." [15–16]

Guidance & Commitments

Key Metrics